Lexaria Bioscience Corp. (LEXX)
NASDAQ: LEXX · Real-Time Price · USD
0.8341
-0.0468 (-5.31%)
At close: Jul 14, 2025, 4:00 PM
0.8300
-0.0041 (-0.49%)
After-hours: Jul 14, 2025, 4:08 PM EDT
Lexaria Bioscience Revenue
Lexaria Bioscience had revenue of $174.00K in the quarter ending February 28, 2025, with 20.00% growth. This brings the company's revenue in the last twelve months to $525.92K, up 29.95% year-over-year. In the fiscal year ending August 31, 2024, Lexaria Bioscience had annual revenue of $464.28K with 105.24% growth.
Revenue (ttm)
$525.92K
Revenue Growth
+29.95%
P/S Ratio
26.69
Revenue / Employee
$75,132
Employees
7
Market Cap
16.28M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Aug 31, 2024 | 464.28K | 238.07K | 105.24% |
| Aug 31, 2023 | 226.21K | -29.19K | -11.43% |
| Aug 31, 2022 | 255.40K | -467.34K | -64.66% |
| Aug 31, 2021 | 722.74K | 407.95K | 129.59% |
| Aug 31, 2020 | 314.79K | 92.18K | 41.41% |
| Aug 31, 2019 | Pro | Pro | Pro |
| Aug 31, 2018 | Pro | Pro | Pro |
| Aug 31, 2017 | Pro | Pro | Pro |
| Aug 31, 2016 | Pro | Pro | Pro |
| Aug 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
LEXX News
- 21 days ago - Lexaria Reaches Patent Milestone - 50 Patents Now Granted Worldwide - TheNewswire
- 4 weeks ago - Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule - TheNewswire
- 5 weeks ago - Lexaria Attending BIO International Convention - TheNewswire
- 2 months ago - Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company - Accesswire
- 2 months ago - Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock - Accesswire
- 2 months ago - Lexaria Announces $2 Million Registered Direct Offering of Common Stock - Accesswire
- 2 months ago - Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience's Technology - Accesswire
- 3 months ago - Lexaria Updates its Ongoing Human Study GLP-1-H24-4 - Accesswire